Clinical Trials Logo
  1. Home
  2. Esophagogastric Cancer
  3. NCT01167114

STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer

Esophagogastric Cancer Clinical Trial

Official title:
A Phase 2 Clinical Trial of STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancers

Clinical Trial Summary

In this research study, the investigators are looking to see how effective STA-9090 is in treating esophagogastric cancer. The investigators will also evaluate the side effects of STA-9090, and examine the relationship between the presence of HSP-90 and how well study participants respond to STA-9090. STA-9090 works by blocking a protein in tumor cells called HSP90, which is thought to play a role in tumor growth. By interfering with this protein's function, STA-9090 may help kill tumor cells. This drug has been used in other research studies and information from those other research studies suggests that this agent may help to slow tumor growth in esophagogastric cancer.

Clinical Trial Description

- Each treatment cycle lasts 4 weeks during which time the study drug will be administered for three consecutive weeks followed by 1 week of no study drug. STA-9090 will be given by intravenous infusion. - Participants will come to the clinic on Days 1, 8, and 15 of all cycles. At these visits, the following tests and procedures will be performed: Review of current medications and any side effects experienced; Performance status evaluation; Physical examination; Vital signs; Routine blood tests; CT scan of the chest, abdomen, and pelvis (every 2 cycles) and Optional FDG-PET scan (every 2 cycles). - Participants may remain on this research study for as long as their cancer is responding to the study drug and they are not experiencing any severe side effects. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01167114
Study type Interventional
Source Massachusetts General Hospital
Contact
Status Completed
Phase Phase 2
Start date August 2010
Completion date April 2017
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05544929 - A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers Phase 1
Recruiting NCT05612048 - A Study of Tooth Erosion in People With Esophagogastric Cancer N/A
Completed NCT04161781 - A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer
Completed NCT01803282 - Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT05796102 - PET-MRI Esophagus Feasibility Study N/A
Recruiting NCT04656041 - Folfox+Irinotecan+Chemort In Esophageal Cancer Phase 2
Withdrawn NCT02296671 - Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers Phase 2
Active, not recruiting NCT04757363 - A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer Phase 2
Completed NCT02023996 - PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer N/A
Recruiting NCT05117931 - A Study of Amivantamab in People With Esophagogastric Cancer Phase 2
Not yet recruiting NCT03760289 - DKN-01/Atezolizumab as Second Line Treatment of biliarY Tract Cancer and in combiNAtion or Not With Paclitaxel as Second Line treatMent of esophagogastrIC Cancer Phase 2
Active, not recruiting NCT03133650 - A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing Phase 1